Player FM 앱으로 오프라인으로 전환하세요!
Tim Moran of Avertix, and Ross Haghighat of BioPlus Acquisition Corp.
Manage episode 377051590 series 2985779
Biotech firms tend to come on to SPACs’ radar when they still have some clinical work to complete to get to an approved medicine or device, but Avertix is ahead of that particular curve.
This week, we speak with Tim Moran, President and CEO of Avertix, and Ross Haghighat, CEO and CFO of BioPlus Acquisition Corp. (Nasdaq: BIOS). The two announced a $195 million dollar combination in May of this year.
Tim tells us how Avertix’s Guardian heart monitoring implant has performed in its initial commercial rollout, having already been approved by the FDA and for insurance reimbursements.
Ross meanwhile explains why being at that stage of the process was important for BioPlus’ criteria given the current market conditions and what further value streams could be unlocked by the Guardian device long term.
98 에피소드
Manage episode 377051590 series 2985779
Biotech firms tend to come on to SPACs’ radar when they still have some clinical work to complete to get to an approved medicine or device, but Avertix is ahead of that particular curve.
This week, we speak with Tim Moran, President and CEO of Avertix, and Ross Haghighat, CEO and CFO of BioPlus Acquisition Corp. (Nasdaq: BIOS). The two announced a $195 million dollar combination in May of this year.
Tim tells us how Avertix’s Guardian heart monitoring implant has performed in its initial commercial rollout, having already been approved by the FDA and for insurance reimbursements.
Ross meanwhile explains why being at that stage of the process was important for BioPlus’ criteria given the current market conditions and what further value streams could be unlocked by the Guardian device long term.
98 에피소드
Todos los episodios
×플레이어 FM에 오신것을 환영합니다!
플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.